Analysts Offer Predictions for OptimizeRx Co.’s Q1 2024 Earnings (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Equities research analysts at William Blair reduced their Q1 2024 earnings per share (EPS) estimates for OptimizeRx in a report issued on Tuesday, April 16th. William Blair analyst R. Daniels now forecasts that the company will earn ($0.34) per share for the quarter, down from their previous forecast of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.59) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

Other equities research analysts also recently issued research reports about the company. JMP Securities reaffirmed a “market outperform” rating and issued a $15.00 target price on shares of OptimizeRx in a research report on Tuesday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Finally, Barclays started coverage on OptimizeRx in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.86.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $9.35 on Thursday. The firm has a market capitalization of $169.98 million, a PE ratio of -9.26 and a beta of 0.98. The business has a 50-day moving average of $13.36 and a two-hundred day moving average of $11.95. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans lifted its holdings in OptimizeRx by 4.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 18,631 shares of the company’s stock worth $276,000 after buying an additional 797 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of OptimizeRx by 1.7% during the 3rd quarter. Nuveen Asset Management LLC now owns 49,959 shares of the company’s stock worth $741,000 after purchasing an additional 842 shares during the period. Captrust Financial Advisors raised its position in shares of OptimizeRx by 248.8% during the 2nd quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock worth $35,000 after purchasing an additional 918 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of OptimizeRx by 2.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 45,103 shares of the company’s stock worth $1,701,000 after purchasing an additional 1,033 shares during the period. Finally, Point72 Hong Kong Ltd raised its position in shares of OptimizeRx by 81.6% during the 2nd quarter. Point72 Hong Kong Ltd now owns 2,492 shares of the company’s stock worth $68,000 after purchasing an additional 1,120 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.